Topics

Triaptosis: A Unique Cell Death Pathway

Cell Programmed Death Cellular Stress Oxidative Stress Proteostasis

Triaptosis is an emerging oxidative, endosome-dependent cell-death modality defined from a 2024 study of menadione sodium bisulfite, a water-soluble vitamin K precursor. The primary paper showed that this pro-oxidant suppressed prostate-cancer progression in mice through a death mechanism linked to the class III phosphatidylinositol 3-kinase VPS34, and later commentaries named the process triaptosis. The evidence base remains narrow: one central mechanistic study, interpretive articles, and early computational signatures dominate the field. Triaptosis should therefore be treated as a developing experimental framework, not as a clinically validated or broadly conserved death pathway[1][2][3].

VPS34, encoded by PIK3C3, generates phosphatidylinositol 3-phosphate and supports endosome identity, cargo sorting, and autophagic trafficking. Menadione sodium bisulfite oxidized critical cysteines in VPS34, antagonizing its lipid-kinase function and disrupting endosomal sorting. The resulting endosomal failure caused lethal oxidative stress that was presented as distinct from established apoptosis, ferroptosis, necroptosis, and pyroptosis. This mechanism creates a redox checkpoint at a trafficking enzyme: instead of oxidants acting only through bulk macromolecular damage, a defined oxidative modification disables an essential membrane-organization system. The dependence on dose, cellular antioxidant capacity, VPS34 activity, and endosomal demand remains to be mapped across cell types[1][2][3].

The clearest application is preclinical prostate-cancer therapy. Dietary menadione sodium bisulfite reduced tumor progression in mouse models, suggesting that pro-oxidant therapy may exploit cancer redox stress while bypassing apoptosis resistance. The same study also applied the compound to myotubular myopathy caused by loss of MTM1, a phosphatase that opposes VPS34: treatment improved muscle histology and function and prolonged survival in the disease model. This unexpected result shows that oxidative VPS34 modulation can have distinct therapeutic objectives—induce death in cancer or rebalance phosphoinositide signaling in inherited muscle disease. It also warns that exposure and tissue context may separate benefit from toxicity[1][2][4].

The relationship between triaptosis and autophagy also requires careful resolution because VPS34 participates in both endosomal and autophagic membrane biology. Loss of phosphatidylinositol 3-phosphate could alter cargo recycling, lysosome delivery, nutrient sensing, and organelle quality control before cells become irreversibly committed. Investigators should determine whether the lethal event arises from one indispensable trafficking cargo, cumulative endosomal collapse, or a secondary metabolic crisis. Tumors with high antioxidant capacity may resist VPS34 oxidation, while cells already dependent on endosomal recycling may be unusually sensitive. These possibilities provide testable biomarkers but cannot be replaced by retrospective correlations between a small gene set and patient survival. A mechanistic definition should remain anchored to oxidant exposure, direct VPS34 modification, endosomal dysfunction, and rescue of viability. Major gaps include nomenclature, selectivity, execution markers, and human relevance. Investigators must determine whether VPS34 oxidation is necessary and sufficient, which endosomal lesions commit cells to die, and whether genetic rescue distinguishes triaptosis from general oxidative poisoning. Menadione derivatives can participate in redox cycling, so systemic effects on liver, blood, heart, and normal proliferative tissues require rigorous pharmacology. Future work should use cysteine-resistant VPS34 variants, quantitative phosphatidylinositol 3-phosphate imaging, endosomal flux assays, and single-cell death reporters across tumor and normal organoids. Biomarkers should measure target oxidation and trafficking failure rather than infer triaptosis from a gene signature. Independent replication, structure-activity studies, and carefully controlled clinical specimens are necessary before triaptosis can guide patient selection or combination therapy[1][2][3][4].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-100523 ML385
ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC50 of 1.9 μM.
Keap1-Nrf2   Ferroptosis  
Lung Cancer   Colorectal Cancer   Ovarian Cancer  
629
HY-16561 Resveratrol
Resveratrol (trans-Resveratrol; SRT501) is a CNS-penetrant natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
DNA/RNA Synthesis   IKK   Autophagy   Mitophagy   Sirtuin   Apoptosis   Bacterial   Fungal   Antibiotic   Keap1-Nrf2  
Neurological, Eye or Ear Disease   Prostate Cancer   Liver Cancer   Bacterial Infection   Fungal Infection   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
172
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
144
HY-N0005 Curcumin
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
Histone Acetyltransferase   Epigenetic Reader Domain   Keap1-Nrf2   Autophagy   Mitophagy   Influenza Virus   Ferroptosis   Apoptosis  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Pain   Digestive System Inflammation   Glucose Metabolism   Metastatic Breast Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
135
HY-100489 TBHQ
TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma.
Environmental Pollutants   Autophagy   ERK   Ferroptosis   Keap1-Nrf2   Apoptosis  
Cancer   Digestive System Disease   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis  
129
HY-N0162 Luteolin
Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells.
Keap1-Nrf2   Apoptosis   Autophagy   Endogenous Metabolite  
Lung Cancer   Colorectal Cancer   Ovarian Cancer   Digestive System Inflammation   Glucose Metabolism   Obesity  
94
HY-112675 4-Octyl itaconate
4-Octyl Itaconate is a cell-permeable Itaconate derivative. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.
Keap1-Nrf2  
Inflammation or Immune System Disease   Obesity   Lung Fibrosis  
94
HY-L007 Immunology/Inflammation Compound Library
The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. MCE designs a unique collection of 8,534 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Signaling Pathway Targeting Libraries

89
HY-L107 Anti-Cancer Natural Product Library
With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers. MCE offers a unique collection of 2,002 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

Disease Focused Libraries Natural Product Screening Libraries

85
HY-L118 Sodium Channel Blocker Library
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 197 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Signaling Pathway Targeting Libraries

83
HY-L124 Anti-Prostate Cancer Compound Library
Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment. MCE offers a unique collection of 3,586 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-13755 Sulforaphane
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.
HDAC   Keap1-Nrf2   Apoptosis   Bcl-2 Family   Caspase   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease  
77
HY-17363 Dimethyl fumarate
Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
Keap1-Nrf2   Reactive Oxygen Species (ROS)   HIV   Autophagy   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Colorectal Cancer   Viral Infection   Obesity   Lung Fibrosis  
64
HY-B0332 Menadione
Menadione is a naphthoquinone that is converted into active vitamin K2 in the body. Menadione is a potential anticancer agent and radiosensitizer.
Environmental Pollutants   Endogenous Metabolite  
Cancer   SARS-CoV-2 Infection  
31
HY-12212 Omaveloxolone
Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
Keap1-Nrf2   STING   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity   Lung Fibrosis  
26
HY-N6687 Calcimycin
Calcimycin (A-23187) is an antibiotic and a unique divalent cation ionophore (like calcium and magnesium). Calcimycin induces Ca2+-dependent cell death by increasing intracellular calcium concentration. Calcimycin inhibits the growth of Gram-positive bacteria and some fungi. Calcimycin also inhibits the activity of ATPase and uncouples oxidative phosphorylation (OXPHOS) of mammalian cells. Calcimycin induces apoptosis and autophagy.

Source: Streptomyces chartreusensis

Oxidative Phosphorylation   Bacterial   Fungal   Apoptosis   Autophagy   Antibiotic  
Cancer   Digestive System Disease   Bacterial Infection   Fungal Infection   Digestive System Inflammation  
26
HY-19734 NK-252
NK-252 is a potential Nrf2 activator, which exhibits a great Nrf2-activating potential.
Quinone Reductase   Keap1-Nrf2  
Cancer   Obesity   Lung Fibrosis  
24
HY-101140 KI696
KI696 is a selective KEAP1/NRF2 protein-protein interaction inhibitor with a human Kd value of 1.3 nM. KI696 acts by competitively occupying the NRF2-binding pocket of the KEAP1 Kelch domain. KI696 blocks KEAP1-mediated ubiquitination and degradation of NRF2, promotes the translocation of NRF2 to the nucleus, activates the expression of downstream antioxidant genes, increases intracellular glutathione levels, and alleviates oxidative stress-induced cell damage and inflammatory cell infiltration in the lungs. KI696 reduces ozone-induced pulmonary oxidative damage and inflammatory cell accumulation in rats, and upregulates pulmonary antioxidant genes. KI696 can be used in research related to chronic obstructive pulmonary disease, oxidative stress and inflammation.
Keap1-Nrf2   Quinone Reductase  
Oxidative Stress and Inflammation   Pulmonary Disease  
23
HY-N0645 Dicoumarol
Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and PDK1 with IC50s of 0.37 and 19.42 μM, respectively.
Quinone Reductase   PDHK  
14
HY-113071 Mevalonic acid
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
12
HY-110258 ML334
ML334 is a potent, cell permeable activator of NRF2 by inhibition of Keap1-NRF2 protein-protein interaction. ML334 binds to Keap1 Kelch domain with a Kd of 1 μM. ML334 stimulates NRF2 expression and nuclear translocation and induces antioxidant response elements (ARE) activity.
Quinone Reductase   Keap1-Nrf2  
Cancer   Obesity   Lung Fibrosis  
12
HY-113071A Mevalonic acid lithium salt
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Cardiovascular Disease  
12
HY-N1990 Gypenoside XLIX
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
PPAR   Sirtuin   Keap1-Nrf2   Toll-like Receptor (TLR)   NF-κB   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   Apoptosis   Pyroptosis   Autophagy  
Neurological, Eye or Ear Disease   Atherosclerosis and Inflammation   Acute Lung Injury   Cardiomyopathy   Liver Injury  
2
HY-30267 4-Hydroxyphenyl acetate
4-Hydroxyphenyl acetate (4-HPA) is a natural antioxidant and protects cells from oxidative stress-induced necrosis. 4-Hydroxyphenyl acetate blocks the increase of cellular ROS induced by oxidative stress, and up-regulates NQO1 and HO-1 genes by stabilizing and inducing the nuclear translocation of NRF2 transcription factor.
Quinone Reductase   Endogenous Metabolite  
Parkinson's Disease  
2
HY-148761 Zadavotide guraxetan
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa).
PSMA  
Prostate Cancer   Triple-Negative Breast Cancer  
2
HY-125865 Casein
Casein is an orally active phosphoprotein that can be separated into various electrophoretic components, such as α2-Casein, κ-Casein, β-casein, and γ-casein. Casein has also been blended and grafted with other polymers, cross-linkers, or monomers to improve its functional properties. Casein enhances calcium absorption and reduces the extent of fissure as well as smooth-surface caries. Casein promotes proliferation of prostate cancer. Casein has various applications in the paper, leather, textile, and food industries, serving as coatings, adhesives, and packaging materials.
Environmental Pollutants   Casein Kinase   Endogenous Metabolite  
Metabolic or Endocrine Disease   Non-Small Cell Lung Cancer  
2
HY-P80251 NQO1 Antibody (YA261)
NQO1 Antibody (YA261) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NQO1.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

2
HY-W009300 4-Hydroxyestrone
4-Hydroxyestrone (4-OHE1) is a brain-penetrant estrogen metabolite. 4-Hydroxyestrone shows neuroprotective effects involving increased cytoplasmic localization of p53 resulting from SIRT1-mediated p53 deacetylation. 4-Hydroxyestrone relies on PDI to mediate its protective effect against chemically induced ferroptosis in estrogen receptor-negative cancer cells. 4-Hydroxyestrone inhibits lipid peroxidation and lipid-ROS accumulation. 4-Hydroxyestrone blocks preovulatory luteinizing hormone surges in Rattus norvegicus. 4-Hydroxyestrone can be used for the researches of neurodegeneration, breast cancer and endocrine disease.
Endogenous Metabolite   Estrogen Receptor/ERR   Sirtuin   MDM-2/p53   PDI   Ferroptosis   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
1
HY-N2456 Mogroside IV-E
Mogroside IV-E is a PUS1 inhibitor that reduces PUS1 expression and inhibits bone metastasis of prostate cancer. Mogroside IV-E can be used in prostate cancer-related research.
DNA/RNA Synthesis  
Prostate Cancer  
1
HY-N6036 Ganoderic acid F
Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress.
Others  
Cancer   Parkinson's Disease   Obesity  
1
HY-W011370 Pelargonidin chloride
Pelargonidin chloride is an anthocyanidin and also is a scavenger of nitric oxide radical and has antioxidant activities. Pelargonidin inhibits cell viability and induces cell cycle arrest at sub-G1 phase. Pelargonidin chloride increases the mRNA and protein expression of HO-1, NQO1, Nrf2. Pelargonidin chloride improves Aβ-induced memory and learning impairment.
Quinone Reductase   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-113217 Cholesteryl oleate
Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing.
Liposome   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
1
HY-128895 KL1333
KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures.
Quinone Reductase   Mitochondrial Metabolism  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
1
HY-107855 DL-Mevalonolactone
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Parkinson's Disease  
1
HY-100367 ES 936
ES 936 is a potent and specific NQO1 inhibitor. ES 936 inhibits the growth of MIA PaCa-2 and BxPC-3 cells, with IC50 values of 108 nM and 365 nM, respectively. ES936 significantly inhitbits the growth rate of MIA PaCa-2 xenograft tumors in mice. ES 936 can be used for the study of pancreatic cancer.
Quinone Reductase   NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
1
HY-111914A Ferroheme
Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].
NO Synthase   Fatty Acid Synthase (FASN)  
Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity  
1
HY-P74405A Azoreductase/NQO1 Protein, Human
Azo reductase/NQO1 protein is a flavin-containing quinone reductase that uses NADH or NADPH to catalyze the two-electron reduction of quinone to hydroquinone. It regulates cellular redox status by detoxifying quinones and reducing plasma membrane redox components. Azoreductase/NQO1 Protein, Human is the recombinant human-derived Azoreductase/NQO1 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

1
HY-P2450 Leucinostatin A
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies.

Source: Paecilomyces lilacinus

Fungal   Antibiotic  
Infection  
/
HY-112005G DOPE (GMP)
DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.
Ferroptosis   Glutathione Peroxidase   ACSL Family   Amino acid Transporter  
Digestive System Disease   Alzheimer's Disease   Colitis  
/
HY-N15637 Torularhodin
Torularhodin is a carotenoid with anti-cancer activity. Torularhodin induces apopotsis of tumor cells and can be used for the study of prostate cancer.

Source: Rhodotorula rubra

Apoptosis  
/
HY-P10611 [D-Ser14]-Humanin
[D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of amyloid-β. Humanin (HY-P1928) inhibits the aging-related death of various cells caused by amyloid fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-P991292 AB-3A4
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

ADC Antibodies  
Cancer  
/
HY-126412 Neochamaejasmine A
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer.
Apoptosis  
/
HY-158498 FA2 glycan (G0F)
FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research.
Biochemical Assay Reagents  
Prostate Cancer  
/
HY-N15449 Vicanicin
Vicanicin is a depsidone compound found in lichens. Vicanicin inhibits the expression of Hsp70, regulates the redox-sensitive mechanisms within cells, promotes the increase of reactive oxygen species (ROS) in cancer cells, changes the Bax/Bcl-2 ratio, activates caspase-3, and triggers apoptosis. Vicanicin inhibits cell growth and induces apoptosis in androgen-sensitive (LNCaP) and androgen-insensitive (DU-145) human prostate cancer cells. Vicanicin is promising for research of prostate cancer.

Source: Psoroma sphinctrinum

HSP   Caspase   Apoptosis   Reactive Oxygen Species (ROS)   Bcl-2 Family  
/
HY-N10491 Spongionellol A
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer.
P-glycoprotein  
/
HY-N0390G L-Glutamine (GMP)
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
mTOR   NF-κB   STAT   HIF/HIF Prolyl-Hydroxylase  
Inflammation or Immune System Disease   Ischemic Stroke   Osteoporosis   Osteoarthritis  
/
HY-19337S1 Ketodarolutamide-d6
Ketodarolutamide-d6 (BAY 1896953-d6) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells. Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs. Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer.
Isotope-Labeled Compounds   Androgen Receptor  
Castration-Resistant Prostate Cancer  
/
HY-D3347 DUPA-FITC
DUPA-FITC is a fluorescent reagent targeting PSMA, which specifically binds to prostate cancer cells expressing PSMA without non-specific binding to normal blood cells. DUPA-FITC can label PSMA-expressing prostate cancer cells in whole blood, followed by internalization and trafficking to acidic intracellular endosomes, during which the fluorescence is quenched. When combined with flow cytometry and density gradient centrifugation enrichment, DUPA-FITC enables quantitative analysis of circulating tumor cells in peripheral blood samples from prostate cancer patients.
Fluorescent Dye  
Prostate Cancer  
/
HY-P11580 Pap12-6-10
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize bacterial cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections.
Toll-like Receptor (TLR)   Bacterial  
Bacterial Infection  
/
HY-P3502A Zilucoplan TFA
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM).
Complement System  
Inflammation or Immune System Disease  
/
HY-D3353 PSMA-SulfoCy7
PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies.
PSMA  
Prostate Cancer  
/
HY-14249S1 (R)-Bicalutamide-d5
(R)-Bicalutamide-d5 is deuterated labeled (R)-Bicalutamide (HY-108250). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.
Androgen Receptor   Autophagy   Isotope-Labeled Compounds  
Cancer  
/
HY-13673S1 Goserelin-d7
Goserelin-d7 (ICI 118630-d7) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds   Apoptosis   GnRH Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-P11310 PSMA-1-SMCC
PSMA-1-SMCC is a selective binding agent targeting Prostate-Specific Membrane Antigen (PSMA). PSMA-1-SMCC is promising for research of targeted imaging for prostate cancer.
PSMA  
Cancer  
/
HY-P991360 MLN 591
MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research.

Species: Human

PSMA  
Cancer  
/
HY-P11638 Mitochondrial-targeted peptide BP29
Mitochondrial-targeted peptide BP29 is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 can be used for the research of Friedreich's ataxia.
Mitochondrial Metabolism  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-107855S4 DL-Mevalonolactone-13C2
DL-Mevalonolactone-13C2 ((±)-Mevalonolactone-13C2) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P11443 SRC2-2 peptide
SRC2-2 peptide is a a coactivator-derived mimic targeting androgen receptor (AR) ligand. SRC2-2 peptide is promising for research of prostate cancer.
Androgen Receptor  
Cancer  
/
HY-16375 Ozarelix
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer.
GnRH Receptor   Apoptosis  
Cancer  
/
HY-19980G Eprenetapopt (GMP)
Eprenetapopt (GMP) (APR-246(GMP)) is Eprenetapopt (HY-19980) in GMP grade. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
MDM-2/p53   Ferroptosis   Autophagy   Apoptosis  
Non-Small Cell Lung Cancer  
/
HY-W088413A DOTA-amide dihydrate
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-107855S2 DL-Mevalonolactone-13C
DL-Mevalonolactone-13C ((±)-Mevalonolactone-13C) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D3189 5GluAF-2MeTG
5GluAF-2MeTG is an activatable fluorescent probe targeting the glutamate carboxypeptidase (CP) activity of PSMA (Ex/Em=490/500-600 nm). After being hydrolyzed by PSMA, 5GluAF-2MeTG releases a cell membrane-permeable fluorescent product, and achieves fluorescence activation by disrupting donor-excited photoinduced electron transfer (d-PeT). 5GluAF-2MeTG enables fluorescence imaging of live PSMA-expressing prostate cancer cells in vitro and visualizes the carboxypeptidase activity of PSMA. 5GluAF-2MeTG can be used to detect prostate cancer regions in preclinical excised tissue specimens.
Fluorescent Dye   PSMA  
/
HY-P5142 ω-Hexatoxin-Hv1a
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons.
Insecticide   Calcium Channel   Apoptosis   Necroptosis  
Atopic Dermatitis   Ischemic Stroke  
/
HY-16498 Tigapotide
Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia.
Apoptosis   PTHR  
Prostate Cancer   Hypercalcemia  
/
HY-19337S Ketodarolutamide-d3
Ketodarolutamide-d3 (BAY 1896953-d3) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells. Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs. Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer.
Isotope-Labeled Compounds   Androgen Receptor  
Castration-Resistant Prostate Cancer  
/
HY-W752587 DL-Mevalonolactone-d4
DL-Mevalonolactone-d4 ( (±)-Mevalonolactone-d4) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-12040S Elesclomol-d2
Elesclomol-d2 (STA-4783-d2) is a deuterium labeled Elesclomol (HY-12040). Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research.
Isotope-Labeled Compounds   Reactive Oxygen Species (ROS)   Apoptosis   Cuproptosis  
/
HY-P991414 FGI-1011A6
FGI-1011A6 is a human monoclonal antibody (mAb) targeting TSG101. FGI-1011A6 can be used in Prostate cancer and Viral infections research.

Species: Human

HIV  
Cancer   Infection  
/
HY-P10951 (R)-Zadavotide guraxetan
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research.
PSMA  
Cancer  
/
HY-B1914S Tebufenpyrad-d3
Tebufenpyrad-d3 is the deuterium labeled Tebufenpyrad (HY-B1914). Tebufenpyrad can induce mitochondrial dysfunction and oxidative damage. Tebufenpyrad induces dose-dependent cell death on N27 cells, with an EC50 value of 3.98 μM.
Isotope-Labeled Compounds   Mitochondrial Metabolism  
Cancer   Neurological, Eye or Ear Disease  
/
HY-N0565AG Doxycycline (hydrochloride) (GMP)
Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
Apoptosis   MMP   Akt   PI3K  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Breast Cancer   Prostate Cancer   Bladder Cancer  
/
HY-113071AR Mevalonic acid lithium salt (Standard)
Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure.
Reference Standards   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-13673S Goserelin-d10
Goserelin-d10 (ICI 118630-d10) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds  
Cancer   Metabolic or Endocrine Disease  
/
HY-P991410 5T4_0108
5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research.

Species: Human

Wnt  
Cancer  
/
HY-113091 DL-α-Tocotrienol
Alpha-Tocotrienol is a vitamin E analog with anti-apoptotic neuroprotective action and antioxidant properties. Alpha-Tocotrienol prevents oxidative stress-independent apoptotic cell death, DNA cleavage, and nuclear morphological changes.

Source: human blood

Apoptosis  
Neurological, Eye or Ear Disease  
/
HY-107855R DL-Mevalonolactone (Standard)
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
Endogenous Metabolite   Reference Standards  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-14249S Bicalutamide-d4
Bicalutamide-d4 is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer.
Isotope-Labeled Compounds   Androgen Receptor   Autophagy  
Cancer  
/
HY-P11638A Mitochondrial-targeted peptide BP29 acetate
Mitochondrial-targeted peptide BP29 acetate is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 acetate protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 acetate prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 acetate can be used for the research of Friedreich's ataxia.
Mitochondrial Metabolism  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-128850R N-Acetyl-D-mannosamine (Standard)
N-Acetyl-D-mannosamine (Standard) is an analytical standard for N-Acetyl-D-mannosamine. This product is intended for research and analytical applications. N-Acetyl-D-mannosamine (ManNAc) is an orally active sialic acid (Sialic Acid) precursor that can prevent hypertension by increasing sialylation of IgG and has potential for use in cardiovascular disease research. N-Acetyl-D-mannosamine activates hypocretin (HCRT) gene expression and alters
Reference Standards   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-13673S2 Goserelin-d7 TFA
Goserelin-d7 (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds   GnRH Receptor   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-W116336B Zinc oxide, 99.99% metals basis
Zinc oxide, 99.99% metals basis is a versatile wide-bandgap semiconductor with superior comprehensive properties. Zinc oxide, 99.99% metals basis serves as raw material for Schottky diodes, functional nanostructures, sensors, energy harvesters and photocatalysts for hydrogen production. Zinc oxide, 99.99% metals basis acts as a non-toxic antibacterial agent and selective cytotoxin against multiple bacteria, fungi and spores. Zinc oxide, 99.99% metals basis induces cancer cell death. Zinc oxide, 99.99% metals basis is applicable to drug delivery, biosensing, bioimaging and researches on cancer, microbial infections and skin diseases.
Biochemical Assay Reagents   Fungal   Bacterial  
Cancer   Bacterial Infection   Fungal Infection  
/
HY-P5142A ω-Hexatoxin-Hv1a TFA
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons.
Insecticide   Necroptosis   Calcium Channel   Apoptosis  
Atopic Dermatitis   Ischemic Stroke  
/
HY-B0332S Menadione-d3
Menadione-d3 is the deuterium labeled Menadione. Menadione, a synthetic naphthoquinone, can be converted to active vitamin K2 in vivo.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-N1524 Quinovic acid
Quinovic acid is triterpene. Quinovic acid can ameliorate the Amyloid-β burden, p53 expression and cholesterol accumulation by deterring the oxidative stress through upregulating the Nrf2/HO-1 pathway. Quinovic acid can induce cancer cells apoptosis by upregulating death receptor 5 (DR5). Quinovic acid can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as lung cancer and Alzheimer’s disease (AD).
Amyloid-β   MDM-2/p53   Apoptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-A0287S Clomiphene-d5 hydrochloride
Clomifene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene)-d5 hydrochloride is a deuterium labeled Clomifene hydrochloride (HY-A0287A). Clomiphene hydrochloride is an orally active ovulation-inducing agent. Clomiphene hydrochloride binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene hydrochloride can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene hydrochloride ameliorates memory impairment in PCOS models. Clomiphene hydrochloride mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene hydrochloride can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer.
Isotope-Labeled Compounds   Estrogen Receptor/ERR  
Cancer   Metabolic or Endocrine Disease  
/
HY-P10896 NOTA-P2-RM26
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT.
Bombesin Receptor  
/
HY-145622 Mecbotamab vedotin
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162).
Antibody-Drug Conjugates (ADCs)   TAM Receptor  
Cancer  
/
HY-P6825 Ancelvotide Guraxetan
PNT2001 (LY4181530) is a high-affinity PSMA-targeted radiopharmaceutical ligand precursor. natLu-PNT2001 has an IC50 of 3.1 nM against PSMA. PNT2001 is applicable for PSMA targeting, radiopharmaceutical ligand delivery, and prostate cancer-related research.
PSMA  
Prostate Cancer  
/
HY-121362 Evernic Acid
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections.
Bacterial   TrxR   Endogenous Metabolite  
Inflammation or Immune System Disease   Breast Cancer   Bacterial Infection   Parkinson's Disease  
/
HY-N7504 Isopsoralenoside
Isopsoralenoside is a benzofuran glycoside and coumarin-derived compound. Isopsoralenoside exists in the dried mature fruits of Psoralea corylifolia L., and acts as a metabolite precursor, toxicant and inducer, with estrogen-like, osteoblast proliferation-promoting, anti-tumor and antibacterial activities. Isopsoralenoside can be deglycosylated by intestinal flora to form isopsoralen. Isopsoralenoside induces oocyte death in zebrafish, activates oxidative stress and cell death-related pathways in zebrafish follicles, and is the main effector substance responsible for the reproductive toxicity induced by Fructus Psoraleae. Isopsoralenoside can be used in studies related to reproductive toxicity (ovarian dysfunction, follicular atresia, impaired fertility).
Bacterial   Reactive Oxygen Species (ROS)  
Cancer   Metabolic or Endocrine Disease   Bacterial Infection  
/
HY-201263 p-SCN-Bn-TCMC
p-SCN-Bn-TCMC is a bifunctional chelator. Its cyclen backbone binds Hg2+, while its isothiocyanate group allows for conjugation to biomolecules. p-SCN-Bn-TCMC can be used in the research of prostate cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-B1817A Zinc acetate, 99.99% trace metals basis
Zinc (Zinc (II)) acetate, 99.99% trace metals basis is a heme oxygenase 1 (HO-1) activator and apoptosis inducer with cytotoxic and anticancer activities. Zinc acetate, 99.99% trace metals basis enhances HO-1 expression, alters the microRNA profile, and increases the level of caspase-cleaved cytokeratin 18. Zinc acetate, 99.99% trace metals basis also regulates the expression of Cdk2/cyclin E and interferes with cell cycle progression. Zinc acetate, 99.99% trace metals basis effectively inhibits cancer cell proliferation and induces their rapid death, with no significant cytotoxicity to non-tumor tissues. Zinc acetate, 99.99% trace metals basis has been widely used in studies related to hepatocellular carcinoma, prostate cancer, and other conditions.
CDK   Heme Oxygenase (HO)   Apoptosis  
/
HY-N7924 Astragenol
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.
Others  
Inflammation or Immune System Disease   Prostate Cancer  
/
HY-16985S Darolutamide-d4
Darolutamide-d4 (ODM-201-d4) is deuterium labeled Darolutamide (HY-16985). Darolutamide (ODM-201) is an orally active competitive androgen receptor (AR) antagonist, with a Ki of 11 nM for rat wild-type AR (wtAR) and an IC50 of 26 nM for human wild-type AR (hAR)-mediated transcriptional activation. Darolutamide inhibits testosterone-induced AR nuclear translocation and transcriptional activation. Darolutamide exerts selective effects on AR-positive cells by inhibiting AR-dependent signaling pathways, and its active metabolite retains full antagonistic activity against AR mutants. Darolutamide can be used for the research of prostate cancer, including androgen receptor-dependent prostate cancer.
Isotope-Labeled Compounds   Androgen Receptor  
Prostate Cancer  
/
HY-P5290 HYNIC-PSMA
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research. HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Radionuclide-Drug Conjugates (RDCs)   PSMA  
/
HY-113152 Hypogeic acid (50mg/ml in ethanol)
Hypogeic acid is a fatty acid and endogenous metabolite, with a concentration of 50 mg/mL in ethanol. The plasma level of Hypogeic acid is negatively correlated with the prevalence of interstitial lung disease in idiopathic inflammatory myopathy. Hypogeic acid can be used in studies related to idiopathic inflammatory myopathy.

Source: Corynebacterium glutamicum

Endogenous Metabolite  
Inflammation or Immune System Disease   Muscle Disease  
/
HY-N3999 Venuloside A
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC50 of 8.12 μM.
Others  
/
HY-P0013 Antide
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.
GnRH Receptor  
Cancer  
/
HY-N7645 Prunetrin
Prunetrin (Trifoside) is a flavonoid identified as a potential anti-prostate cancer agent in in silico screening.
Others  
Prostate Cancer  
/
HY-W010451 1,2,4-Trihydroxybenzene
1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) is an ER stress inducer that targets proteins such as PKR-like ER kinase PERK to induce cytotoxicity. 1,2,4-Trihydroxybenzene selectively activates eIF2α phosphorylation, activates the PERK-eIF2α signaling pathway and induces stress granule formation. 1,2,4-Trihydroxybenzene subsequently exacerbates oxidative stress and causes DNA double-strand breaks, destroying organelles such as mitochondria and ER, and inducing cell death. 1,2,4-Trihydroxybenzene also has the potential to exhibit anti-tumor effect, increase blood pressure, and relieve spasm.

Source: Phanerochaete chrysosporium

PERK   Apoptosis   Potassium Channel   Eukaryotic Initiation Factor (eIF)  
Cancer   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease  
/
HY-B0332R Menadione (Standard)
Menadione (Standard) is the analytical standard of Menadione. This product is intended for research and analytical applications. Menadione is a naphthoquinone that is converted into active vitamin K2 in the body. Menadione is a potential anticancer agent and radiosensitizer.
Reference Standards   Endogenous Metabolite  
/
HY-W008168 Quinoline-2-carboxaldehyde
Quinoline-2-carboxaldehyde (2-Quinolinecarboxaldehyde) is a quinoline derivative that serves as a synthetic precursor for Schiff base copper complexes. Quinoline-2-carboxaldehyde is applicable to research related to the synthetic design of biomaterials or organic compounds, such as fluorescent sensors.
Drug Intermediate  
/
HY-135700 Mevalonolactone
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (Ka = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy.

Source: Pestalotiopsis sp.

Calcineurin   Ras   HMG-CoA Reductase (HMGCR)  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N0754 Eupalinolide A
Eupalinolide A is a Yes-associated protein (YAP) degrader and HSP70 inducer. Eupalinolide A inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs). Eupalinolide A induces autophagy in hepatocellular carcinoma cells via activating the ROS/ERK signaling pathway. Eupalinolide A protects PAM212 cells from UVB-, Menadione (HY-B0332)-, or heat shock-induced apoptosis. Eupalinolide A alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon and inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in mice. Eupalinolide A can be used for the study of traumatic heterotopic ossification of tendons and hepatocellular carcinoma.
YAP   HSP   Reactive Oxygen Species (ROS)   ERK   Autophagy   Apoptosis   Tyrosinase   DNA/RNA Synthesis  
Liver Cancer   Depression   Pain   Digestive System Inflammation  
/
HY-N2122 Neoisoliquiritin
Neoisoliquiritin (Neoisoliquiritigenin) is an androgen receptor (AR) inhibitor. Neoisoliquiritin inhibits the ATPase activity of GRP78. Neoisoliquiritin induces G0/G1 cell cycle arrest and inhibits proliferation in cancer cells, while it also induces cell apoptosis (apoptosis). Neoisoliquiritin suppresses tumor growth in mouse models of prostate cancer and breast cancer. Neoisoliquiritin can be used in studies related to prostate cancer and breast cancer.
Androgen Receptor   HSP   Apoptosis  
Breast Cancer   Prostate Cancer  
/
HY-N0610AS Cinnamic acid-d6
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Endogenous Metabolite  
/
HY-W782083 p-SCN-Bn-NOTA trihydrochloride
p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as 64Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer.
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)   Bombesin Receptor   EGFR  
/
HY-P10409 SHLP2
SHLP2 (Small humanin-like peptide 2) is a small molecule peptide encoded by mitochondrial DNA, belonging to mitochondria derived peptide. SHLP2 has the activity of regulating apoptosis and inhibits cell death. SHLP2 binds to mitochondrial complex 1. SHLP2 improves mitochondrial metabolism by increasing respiration and biogenesis, reducing ROS, and decreasing mtDNA oxidation. SHLP2 also regulated energy homeostasis through the activation of hypothalamic neurons. SHLP2 can be used in the study of diseases related to mitochondrial dysfunction and anti-aging diseases, such as age-related macular degeneration and Parkinson’s disease.
Apoptosis   Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P9992 Pelgifatamab
Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer.

Species: Human

PSMA   Apoptosis  
Castration-Resistant Prostate Cancer  
/
HY-P10646 Muscle homing peptide M12
Muscle homing peptide M12 is a muscle-homing peptide with high affinity for skeletal muscle and cardiac muscle. Muscle homing peptide M12 can mediate the targeted delivery of loaded drugs to skeletal muscle and cardiac muscle tissues.
Others  
/
HY-12346 FH1
FH1 (NSC 12407) is a NQO2 inhibitor with hepatoprotective effects. FH1 enhances hepatocyte function and promotes differentiation of induced pluripotent stem (iPS)-derived hepatocytes to a more mature phenotype and maturation of well-differentiated hepatocyte-like cell (iHeps) cultures. FH1 protects against Acetaminophen (HY-66005)-induced hepatotoxicity in both embryos and adult zebrafish.
Quinone Reductase  
/
HY-164729 FZ-AD005
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer.
Antibody-Drug Conjugates (ADCs)   Topoisomerase   Apoptosis  
Prostate Cancer   Small Cell Lung Cancer  
/
HY-P99183 Abituzumab
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.

Species: Human

Integrin  
Prostate Cancer  
/
HY-13543 Tretazicar
Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1).
Quinone Reductase   DNA Alkylator/Crosslinker  
Lung Cancer  
/
HY-P3502 Zilucoplan
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM).
Complement System  
Musculoskeletal and Skin Disease  
/
HY-W054292 tert-Butyl-DCL
Tert-Butyl-DCL is a PSMA inhibitor. Tert-Butyl-DCL Tert-Butyl-DCL can be used in the research of prostate cancer.
PSMA  
Prostate Cancer  
/
HY-P99189 Cixutumumab
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

Species: Human

IGF-1R  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Metastatic Breast Cancer  
/
HY-128850 N-Acetyl-D-mannosamine
N-Acetyl-D-mannosamine (ManNAc) is an oral active sialic acid precursor that can prevent hypertension by increasing sialylation of IgG, making it a promising candidate for cardiovascular disease research. Additionally, N-Acetyl-D-mannosamine can activate hypocretin (HCRT) gene expression in orexin neurons and improve neurodegeneration caused by aging, offering potential avenues for research in neurological disorders.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Cardiovascular Disease  
/
HY-P991503 Anti-STEAP2 Antibody
Anti-STEAP2 Antibody (AZD0516 antibody) is an antibody targeting six-transmembrane epithelial antigen of the prostate 2 (STEAP2). Anti-STEAP2 Antibody can be used for the synthesis of the ADC molecule AZD0516 (HY-173639). Anti-STEAP2 Antibody can be used in the research of prostate cancer.

Species: Human

ADC Antibodies  
Prostate Cancer  
/
HY-131498 Mca-PLGL-Dpa-AR-NH2
MOCAc-PLGL (Dpa) AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) is a synthetic fluorescent substrate mainly used for in vitro enzymatic activity assays of MMP-7 (detection at 393 nm after excitation at 328 nm). MOCAc-PLGL (Dpa) AR is specifically cleaved and hydrolyzed by MMP-7 at the Gly-Leu peptide bond, allowing enzymatic activity to be monitored via fluorometry or HPLC (DMSO is usually added to ensure sufficient dissolution when determining kinetic parameters). MOCAc-PLGL (Dpa) AR is used to accurately evaluate the catalytic activity and pH dependence of recombinant mature human MMP-7 in vitro. MOCAc-PLGL (Dpa) AR is suitable for research on the mechanisms of tumor metastasis and invasion, particularly in fields such as prostate cancer, colon cancer, lung cancer and breast cancer.\n
Fluorescent Dye   MMP  
Cancer   Digestive System Cancer   Urogenital Cancer  
/
HY-P991015 Pasritamig
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P99239 Rosopatamab
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency.

Species: Human

PSMA   Radionuclide-Drug Conjugates (RDCs)  
Prostate Cancer  
/
HY-P74405 Azoreductase/NQO1 Protein, Human (His)
Azo reductase/NQO1 protein is a flavin-containing quinone reductase that uses NADH or NADPH to catalyze the two-electron reduction of quinone to hydroquinone. It regulates cellular redox status by detoxifying quinones and reducing plasma membrane redox components. Azoreductase/NQO1 Protein, Human (His) is the recombinant human-derived Azoreductase/NQO1 protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P71733 ERG Protein, Human (P.pastoris, His)
ERG Protein, a transcriptional regulator, recruits SETDB1 histone methyltransferase to modify local chromatin. It interacts with SETDB1 and is identified in an IGF2BP1-dependent mRNP granule complex with untranslated mRNAs. ERG Protein, Human (P.pastoris, His) is the recombinant human-derived ERG protein, expressed by P. pastoris , with N-6*His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P74234 Cofilin-2 Protein, Human (His)
Cofilin-2 protein controls actin polymerization and depolymerization in a pH-sensitive manner. Cofilin-2 Protein, Human (His) is the recombinant human-derived Cofilin-2 protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

/
HY-P71831 Azoreductase/NQO1 Protein, Mouse (P.pastoris, His)
The azoreductase/NQO1 protein reduces quinones to hydroquinone using NADH or NADPH as an electron donor.Azoreductase/NQO1 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived Azoreductase/NQO1 protein, expressed by P.pastoris , with N-6*His labeled tag.

Species: Mouse; Source: P. pastoris

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P701752 PK3C3 Protein, Human (Active, sf9, His, GST)
The PI3KC3 protein is the catalytic subunit of the PI3K complex and mediates the formation of phosphatidylinositol 3-phosphate. PI3KC3-C1 initiates autophagosomes, whereas PI3KC3-C2 promotes autophagosome maturation and endocytosis. PK3C3 Protein, Human (sf9, His, GST) is the recombinant human-derived PK3C3 protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Lipid Kinase PI3K PIK3C3

/
HY-P72264 TPM2 Protein, Human (His)
The TPM2 protein binds actin filaments in muscle and nonmuscle cells and centrally regulates calcium-dependent striated muscle contraction in vertebrates, particularly in concert with the troponin complex. In smooth muscle cells, TPM2 helps regulate contraction by interacting with calcium-binding proteins. TPM2 Protein, Human (His) is the recombinant human-derived TPM2 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P78027 PSMP Protein, Human (HEK293, Fc)
PSMP Protein acts as a ligand for CCR2, inducing chemotaxis and calcium mobilization. It attracts monocytes and lymphocytes, not neutrophils. It contributes to neuropathic pain and enhances synaptic transmission in dopamine neurons. PSMP Protein exists as a monomer or homodimer, binding to endothelial cells via proteoglycans. It interacts with TNFAIP6. PSMP Protein, Human (HEK293, Fc) is the recombinant human-derived PSMP protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors

/
HY-P77823 PSMP Protein, Mouse (HEK293, Fc)
PSMP protein, acting as a CCR2 ligand, induces a robust chemotactic response and intracellular calcium mobilization in monocytes and lymphocytes, while having no impact on neutrophils. PSMP Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PSMP protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors

/
HY-P73700 PRAC Protein, Human (His-SUMO)
PRAC Protein exhibits high expression in the prostate, rectum, and distal colon, with weaker expression in the bladder. Its prominence in prostate cancer cell lines suggests a potential link to prostate cancer pathology. The tissue-specific expression emphasizes PRAC Protein's potential roles in normal physiological processes and cancer contexts. PRAC Protein, Human (His-SUMO) is the recombinant human-derived PRAC protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Species: Human; Source: E. coli

/
HY-P703032 TRIB1 Protein, Human (sf9, GST)
TRIB1 Protein, Human (sf9, GST) is the recombinant human-derived TRIB1, expressed by Sf9 insect cells , with GST labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Isomerases (EC 5)

/
HY-P80250 NQO1 Antibody (YA697)
NQO1 Antibody (YA697) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to NQO1.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P87094 Slow Skeletal Myosin Heavy chain Antibody (YA6787)
Slow Skeletal Myosin Heavy chain Antibody (YA6787) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Slow Skeletal Myosin Heavy chain.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83044 PI3 Kinase Class 3 Antibody (YA2789)
PI3 Kinase Class 3 Antibody (YA2789) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase Class 3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86969 MYH2 Antibody (YA6662)
MYH2 Antibody (YA6662) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MYH2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81365 SLC45A3 Antibody (YA1110)
SLC45A3 Antibody (YA1110) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SLC45A3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81365A SLC45A3 Antibody (YA1110)(PBS only)
SLC45A3 Antibody (YA1110) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SLC45A3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85009 CD82 Antibody (YA4701)
CD82 Antibody (YA4701) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD82.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Nanobodies Primary Antibodies

/
HY-P810413 NQO2 Antibody (YA9728)
NQO2 Antibody (YA9728) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to NQO2.

Host: Rabbit; Reactivity: Human, Rat, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86526 NQO1 Antibody (YA6218)
NQO1 Antibody (YA6218) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NQO1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/

Keywords

triaptosis | VPS34 | PIK3C3 | menadione sodium bisulfite | oxidative cell death | endosomal dysfunction | phosphatidylinositol 3-phosphate | prostate cancer | redox therapy | myotubular myopathy